Researchers have already identified several cytokines that are involved in the disease, such as TNF‐α, IL‐12, IL‐23, IL‐17A, IL‐17F, and IL‐36, and in the future, tailoring targeted therapy according to a patient's individual immunophenotype may significantly improve the treatment of pediatric psoriasis. Here, TNF is linked to psoriasis.